Suspension of marketing authorisation for ingenol mebutate.

Suspension of marketing authorisation for ingenol mebutate.
Br J Dermatol. 2020 Jun 24;:
Authors: Mohd Mustapa MF, de Berker D, McGregor JM, Exton LS, Hughes BR, Levell NJ
Abstract
The authors of the British Association of Dermatologists' (BAD) clinical guidelines for managing actinic keratosis and the BAD's Therapy & Guidelines sub-committee wish to notify readers of the 2017 guideline publication that the marketing authorisation for ingenol mebutate has been suspended by the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) on 27th January 2020. This is due to emerging evidence suggesting possible links between use of the product with an increased risk of developing skin cancers. The manufacturers are recalling all stocks of this medication. Further advice is available at the MHRA website.
PMID: 32583502 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - June 23, 2020 Category: Dermatology Authors: Mohd Mustapa MF, de Berker D, McGregor JM, Exton LS, Hughes BR, Levell NJ Tags: Br J Dermatol Source Type: research